ReviewAustralian prescriber2018
Drugs for benign prostatic hypertrophy.
Review in Australian prescriber, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Bladder infusion versus standard catheter removal for trial of void: a systematic review and meta-analysis.World journal of urology · 2021Pooled it
- Trial
- Tamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription.Journal of clinical medicine research · 2024Review
- Fucoidan Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Rats.Research and reports in urology · 2024Article
- Inhibitory effects ofIranian journal of basic medical sciences · 2023Article
- Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway.Redox report : communications in free radical research · 2021Article
- A phytosterol-enriched saw palmetto supercritical COBMC complementary and alternative medicine · 2019Article
- Efficacy and tolerability ofTherapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
benign prostatic hyperplasia is a common condition it can cause problems with urine storage and voiding and the severity of symptoms may be unrelated to the size of the prostateWHEN DRUG TREATMENT IS REQUIRED BENIGN PROSTATIC HYPERPLASIA CAN BE MANAGED WITH MONOTHERAPY OR COMBINATION THERAPY MOST PATIENTS ARE MANAGED WITH SELECTIVE ALPHA BLOCKERS: PATIENTS WITH LARGER PROSTATE VOLUMES MAY BENEFIT FROM A 5-ALPHA-REDUCTASE INHIBITOR USUALLY IN COMBINATION WITH AN ALPHA BLOCKER:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.